Screener / SEC EDGAR /CIK 0001114483 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Integer Holdings Corp ITGR

Compare with peers Embed
The 10-K against last year's

186 changes: 38 added, 29 removed, 117 reworded, 2 quiet changes

10-K Feb 23, 2026 vs Feb 20, 2025

10-K 0001114483-26-000003 (Feb 23, 2026) vs 10-K 0001114483-25-000034 (Feb 20, 2025) Not compared: Legal Proceedings, Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

145 paragraphs · 22 new · 48 reworded · 1 gone · 10-K Feb 23, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 11 · 50% changed Every version of it
If we are not successful in making acquisitions able to expand and develop match our business, manufacturing capacity with demand for our operating products, our financial results may suffer.
Paragraph 15 · 49% changed Every version of it
Our products are designed and manufactured in facilities located around the world. In most cases, the manufacturing of specific product lines is concentrated in one or a few locations. If an event (including any weather or natural disaster-related event or a resurgence of the COVID-19 pandemic or other similar pandemic event) occurred that resulted in material damage, loss or incapacitation of one or more of these manufacturing facilities or if we lacked sufficient labor to fully operate any of our facilities, we may not be able to transfer the manufacture of the relevant products to another facility or location in a cost-effective or timely manner, if at all. This potential inability to transfer production could occur for a number of reasons, including but not limited to a lack of necessary relevant manufacturing capability or capacity at another facility, or the regulatory requirements of the FDA or other governmental regulatory bodies. Other disruptions in our manufacturing operations for any reason, including equipment malfunction, failure to follow specific protocols and procedures, or environmental factors could lead to an inability to supply our customers with our products, unanticipated costs, lost revenues and damage to our reputation. In addition, our business involves complex manufacturing processes and the use of various hazardous materials, chemicals and other regulated substances, such as trichloroethylene, which can be dangerous to our associates. We must also comply with various health and safety regulations in the U.S. and abroad in connection with our operations. Although we employ safety procedures in the design and operation of our facilities, there is a risk that an accident or death could occur. Any accident, such as a chemical spill or fire, could result in significant manufacturing delays or claims for damages resulting from injuries, which would harm our business, results of operations and financial condition. The potential liability resulting from any such accident or death, to the extent not covered by insurance, could harm our financial condition or operating results. Any disruption of operations at any of our facilities, and in particular our larger facilities, could result in production delays, which could adversely affect our operations and harm our business.
Paragraph 40 · 43% changed Every version of it
We sell our products to customers in several industries that are characterized by extensive research and development, rapid technological changes, new product introductions and evolving industry standards. To be successful, we must anticipate our customers’ needs and demands, as well as potential shifts in preferences. Without the timely introduction of new products, technologies and enhancements, our products and services will likely become technologically obsolete or less competitive over time and we may lose or see a reduction in business from a significant number of our customers. We dedicate a significant amount of effort and resources to the development of our products, technologies and enhancements. Our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, develop or acquire new technologies and enhancements (including but not limited to artificial intelligence), secure intellectual property protection for our products, and manufacture products in a cost-effective manner. In addition, we would be harmed if our products and technologies do not meet customer requirements and expectations. Our inability, for technological or other reasons, to successfully develop and introduce new and innovative products, technologies and enhancements could result in a loss of customers and lower revenues.
Paragraph 88 · 41% changed Every version of it
Certain provisions in the 2028 Convertible Notes and or the indenture governing the 2028 Convertible Notes could make it more difficult or more expensive for a third party to acquire us. For example, if a takeover constitutes a fundamental change, holders of the 2028 Convertible Notes will have the right to require us to repurchase their notes in cash. In addition, if a takeover constitutes a make-whole fundamental change (as defined in the indenture governing the 2028 Convertible Notes), we may be required to increase the conversion rate for holders of the 2028 Convertible Notes who convert their notes in connection with such takeover. In either case, and in other cases, our obligations under the 2028 Convertible Notes and the indenture governing the 2028 2030 Convertible Notes could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that holders of our common stock may view as favorable.
Paragraph 80 · 32% changed Every version of it
Additionally, our failure to comply with the covenants contained in the 2021 Credit Agreement governing our Senior Secured Credit Facilities, if not waived, could cause a default under our Senior Secured Credit Facilities that requires repayment in full, or acceleration, of debt payments. If that were to occur, there can be no assurance that we would be able to refinance or obtain a replacement financing on favorable terms or at all.
Paragraph 41 · 28% changed Every version of it
We sell our products to customers in several industries that are characterized by extensive research and development, rapid technological changes, new product introductions and evolving industry standards. Without the timely introduction of new products, technologies and enhancements, our products and services will likely become technologically obsolete or less competitive over time and we may lose or see a reduction in business from a significant number of our customers. We dedicate a significant amount of effort and resources to the development of our products, technologies and enhancements. Rapid advancements in AI may also require us to adapt our products and capabilities more quickly than in the past, and our failure to effectively adopt or integrate AI technologies could make our products less competitive. Our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, develop or acquire new technologies and enhancements (including but not limited to artificial intelligence), AI), secure intellectual property protection for our products, and manufacture products in a cost-effective manner. In addition, we would be harmed if our products and technologies do not meet customer requirements and expectations. Our inability, for technological or other reasons, to successfully develop and introduce new and innovative products, technologies and enhancements could result in a loss of customers and lower revenues. Moreover, once introduced, new products may materially and adversely impact sales of our existing products or make them less desirable or even obsolete, which could materially and adversely impact our revenues and operating results.
Paragraph 79 · 27% changed Every version of it
Additionally, our failure to comply with the covenants contained in the 2021 Credit Agreement governing our Senior Secured Credit Facilities, if not waived, could cause a default under our Senior Secured Credit Facilities that requires repayment in full, or acceleration, of debt payments. If that were to occur, there can be no assurance that we would be able to refinance or obtain a replacement financing on favorable terms or at all.
Paragraph 94 · 27% changed Every version of it
We are subject to counterparty risk with respect to the capped call transactions. transactions for the 2028 Convertible Notes and the 2030 Convertible Notes.

MD&A

96 paragraphs · 16 new · 41 reworded · 28 gone · 10-K Feb 23, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 28 · 49% changed
•Other (income) loss, net for 2025 and 2024 and 2023 were losses of $3.5 was $53.2 million and $1.0 $3.5 million, respectively, primarily due driven by a $46.7 million of debt conversion inducement expense recorded in 2025 related to fluctuations in foreign currency gains and losses in the respective periods. partial exchange of our outstanding 2028 Convertible Notes during the first quarter of 2025.
Paragraph 6 · 48% changed
Our future results of operations and liquidity could be materially adversely affected by uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, elevated interest rates, disruptions in the commodities’ markets as a result of the conflict between Russia and Ukraine and conflicts in the Middle East, including Israel and Iran, and the introduction of or changes in tariffs or trade barriers. The impact of these issues on our business will vary by geographic market and product line, but specific impacts to our business include increased borrowing costs, labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, delays in shipments to and from certain countries and potential increased expenses resulting from tariffs or other trade barriers. We monitor economic conditions closely. In response to reductions in revenue, we can take actions to align our cost structure with changes in demand and manage our working capital. However, there can be no assurance as to the effectiveness of our efforts to mitigate any impact of the current and future adverse economic conditions and other developments.
Paragraph 14 · 47% changed
Subsequent to the end of the 2024, on On January 7, 2025, we acquired substantially all of the assets and assumed certain liabilities of certain subsidiaries of Katahdin Industries, Inc., including its main operating subsidiary, Precision Coating LLC (collectively “Precision”). Precision. Prior to the acquisition, Precision was a privately-held manufacturer specializing in high value surface coating technology platforms, including fluoropolymer, anodic coatings, ion treatment solutions and laser processing. Based in Massachusetts, Precision has additional locations in the New England area and an additional facility in Costa Rica. The acquisition of Precision increased our service offerings to include differentiated and proprietary coatings capabilities that position us to better meet customers’ evolving needs. Given the January 7, 2025 closing date of the acquisition, Precision’s results are not included in this MD&A and the disclosures included herein. Refer to Note 21, “Subsequent Events,” of the Notes to Consolidated Financial Statements contained in Item 8, “Financial Statements and Supplementary Data,” of this report for additional information about the acquisition of Precision.
Paragraph 33 · 47% changed
Gross profit as a percent of sales (“Gross margin”) for 2024 2025 increased 40 30 basis points compared to 2023. The improved year over year 2024. Gross margin, or gross profit as a percentage of sales, has been and will continue to be affected by a variety of factors, including the average sales price of our products and services and transaction volume growth. We expect our gross margin was primarily driven by higher sales volume leverage and efficiencies realized through our manufacturing excellence initiatives. to fluctuate over time depending on the factors described above.
Paragraph 56 · 47% changed
See A more detailed analysis of differences between the U.S. federal statutory rate and the consolidated effective rate, as well as other information about our income tax provisions, is provided in Note 9, “Debt,” 13, “Income Taxes,” of the Notes to the Consolidated Financial Statements contained in Item 8, “Financial Statements and Supplementary Data,” of this report for a further information of our outstanding debt. Data.”
Paragraph 17 · 45% changed
On October 31, 2024, we completed the sale of our wholly-owned subsidiary Electrochem Solutions, Inc. (“Electrochem”) for a total purchase price of $50.0 million in cash, subject to customary working capital adjustments. Electrochem, (“Electrochem”), which focused on nonmedical applications for the energy, military and environmental sectors, represented substantially all sectors. As a result of the assets and Electrochem divestiture, the results of operations in our previously reported Non-Medical reporting segment. Subsequently to of the divestiture of Electrochem, we operate in one reportable segment. Electrochem business have been classified as discontinued operations for all periods presented.
Paragraph 36 · 44% changed
(c)Professional fees increased primarily due to increased costs associated with third-party information technology services and higher legal expense related to general corporate matters. and consulting fees.
Paragraph 32 · 42% changed
Other Markets sales for 2024 were flat 2025 decreased $28.7 million, or 27%, in comparison to 2023, as 2024, driven by the decline in Portable Medical from the multi-year exit announced in 2022 was offset by the Pulse acquisition. 2022. Foreign currency exchange rate fluctuations did not have a material impact on Other Markets sales for 2025 in comparison to 2024.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors229 words changed in this paragraph; it is 67% similar to last year's version.
Our business is also subject to potential increased costs and expenses and others other risks resulting from existing and potential future U.S. and foreign legislation, regulations regulations, trade agreements, tariffs, trade wars, import restrictions, boycotts, embargoes, government investigations, trade policies and trade agreements compliance matters relating to the products we manufacture outside of the U.S and import into the U.S. and other materials we import, import for the production of products, including the tariffs on steel and copper that the U.S. has imposed, the imposed and other tariffs that the new current U.S. presidential administration has imposed or threatened to impose, particularly relating to imports into the U.S. from Canada, Mexico (where we currently manufacture a significant portion of our products) and China, Ireland, and other China. Additionally, government actions on quotas, duties, tariffs or taxes or restrictions on imports, all or any of which could adversely affect our operations, increase the costs of products that we manufacture outside the U.S. or adversely impact our profits or margins. Adverse changes in import costs and restrictions, including tariffs, or the failure by us or our suppliers to comply with trade regulations or similar laws, could harm our business. If additional tariffs or trade restrictions are implemented by the U.S. or other countries in connection with a global trade war, the cost of our products manufactured in Mexico or other countries and imported into the U.S. or other countries could increase further, which, in turn, could adversely affect the demand for these products, make our products less competitive and have an adverse effect on our business and results of operations. Further such tariffs and, if enacted, any further legislation or actions taken by the U.S. federal government that restrict trade, such as additional tariffs, trade barriers, and other protectionist or retaliatory measures taken by governments in Europe, Asia, and other countries, could adversely impact our ability to sell products in our international markets. We cannot predict whether new or additional U.S. and foreign trade actions such as customs quotas, duties (including antidumping or countervailing duties), duties, tariffs, taxes or other charges or restrictions, requirements as to where raw materials must be purchased or other restrictions on our imports will be imposed in by the future U.S. government or adversely modified, or what the governments of other countries, and such actions may have a material adverse effect any such future actions would have on our costs of operations. Future quotas, duties or tariffs may adversely affect our business, financial condition, results of operations or conditions and cash flows. In addition, future trade agreements or a global trade war could also provide our competitors with an advantage over us, or increase our costs, either of which could adversely affect our business, financial condition, results of operations or cash flows. flow.

Source: Item 1A, 10-K 0001114483-26-000003 vs Item 1A, 10-K 0001114483-25-000034

MD&A218 words changed in this paragraph; it is 30% similar to last year's version.
During In February 2023, we issued $500 million aggregate principal amount of notes. The 2028 Convertible Notes mature on February 15, 2028 and bear interest at a fixed rate of 2.125% per annum. The conditions allowing holders In March 2025, in connection with the issuance of the 2030 Convertible Notes, the Company used part of the net proceeds therefrom to exchange $383.7 million in aggregate principal amount of the 2028 Convertible Notes to convert the 2028 Convertible Notes were met as of June 30, 2024 and, thereafter, continued to be met as in privately-negotiated transactions. As of December 31, 2024, in each instance due to 2025, the trading price of our common stock exceeding 130% remaining aggregate principal amount of the 2028 Convertible Notes conversion price on at least 20 out of the 30 consecutive trading days prior to such date. Therefore, the 2028 Convertible Notes became eligible for conversion at the option of the holders beginning on July 1, 2024 and will continue to be eligible for conversion through March 31, 2025. Any determination regarding the convertibility of the 2028 Convertible Notes during future periods will be made in accordance with the terms of the indenture governing the 2028 Convertible Notes. If a conversion request occurs, we have the intent and ability to refinance the amounts that may become due with respect to the 2028 Convertible Notes using available borrowing capacity under the Revolving Credit Facility. As such, the obligations associated with the 2028 Convertible Notes continue to be classified as a long-term liability on the Consolidated Balance Sheets as of December 31, 2024. was $116.3 million.

Source: Item 7, 10-K 0001114483-26-000003 vs Item 7, 10-K 0001114483-25-000034

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ITGR's Risk Factors and MD&A, 10-K Feb 23, 2026 against 10-K Feb 20, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Many of our products have a long production cycle, and we must anticipate demand for our products to ensure adequate manufacturing and testing capacity and make certain decisions based on our estimates, including determining the levels of business that we will seek and accept, production schedules, component procurement commitments, working capital management, facility and capacity requirements, facility footprint planning, personnel needs and other resource requirements. Rapid increases in customer demand may stress personnel and other capacity resources. If we are unable to anticipate demand, and our manufacturing or testing capacity does not keep pace with product demand, we will be unable to fulfill orders in a timely manner, which could result in a loss of business from such customer and may negatively impact our financial results and overall business. Conversely, if demand for our products decreases, the fixed costs associated with excess manufacturing capacity may harm our financial results, including by decreasing gross margins and increasing research and development costs as a percentage of revenue.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
or proceedings against us. In certain circumstances, we may rely on third-party vendors to process, store and transmit data for our business whose operations are subject to similar risks. While we conduct security risk assessments prior to engaging third party suppliers and other vendors and business partners to validate that they maintain appropriate safeguards to protect our and their information systems in connection with the services they provide, as described below in greater detail under Item 1C, “Cybersecurity,” it is possible that they suffer a cybersecurity attack, including one amplified by the use of AI-based tools, that negatively impacts us. These risks could have a material adverse effect on our business, financial condition and results of operations. If we are unable to protect our business against or efficiently respond to cybersecurity attacks, it could have a material adverse impact on our business, results of operations and financial condition.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Heightened geopolitical tensions and resulting trade restrictions, including escalating or retaliatory tariffs between regions, could increase the cost of our products or otherwise make products manufactured in certain locations less competitive in key markets, which could reduce customer demand and impair our ability to successfully market our current or future products.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
In addition, some of our competitors outside of the U.S. may have resources and support from their governments that we do not, such as preferences for local manufacturers, and may not be subject to the same tariffs, trade policies, trade compliance regulations and government investigations as us.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Our competitors are not all subject to the same standards, regulatory and/or other legal requirements to which we are subject and, therefore, they could have a competitive advantage in developing, manufacturing, and marketing products and services. Any inability to develop, gain regulatory approval for, and supply commercial quantities of competitive products to existing and potential customers as quickly and effectively as our competitors could limit acceptance of our products and negatively and materially affect our operating results.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
The price of our common stock has been and is likely to continue to be volatile. For example, between January 1, 2025 and February 18, 2026, our common stock’s daily closing price on NYSE has ranged from a low of $63.32 to a high of $144.36. Some companies that have experienced volatility in the trading price of their stock have been the subject of securities litigation. We are currently experiencing securities class action litigation and may experience more such litigation following recent or future periods of volatility or declines in our stock price. For more information, see Note 14, “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements contained in Item 8, “Financial Statements and Supplementary Data,” of this report. Any securities litigation could result in substantial costs and divert our management’s attention and resources, which could adversely affect our business.
Read it in 10-K Feb 23, 2026 at sec.gov
Show the other 55
AddedRisk Factors
We cannot guarantee that we will repurchase our common stock pursuant to our share repurchase program or that our share repurchase program will enhance long-term stockholder value. Share repurchases could also increase the volatility of the price of our common stock and could diminish our cash reserves.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
On November 4, 2025, we announced that our Board of Directors had approved a share repurchase program with no expiration date, under which we are authorized to repurchase shares of common stock for up to $200 million on the open market, in privately-negotiated purchases, including accelerated share repurchases, or otherwise. As of December 31, 2025, approximately $150 million remained available under the program.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Although the Board of Directors has authorized the share repurchase program, the share repurchase program does not obligate the Company to repurchase any specific dollar amount or to acquire any specific number of shares. The timing and amount of repurchases will depend upon several factors, including market and business conditions, the trading price of our common stock and the nature of other investment opportunities. Our ability to repurchase shares of stock may be limited by restrictive covenants in our debt agreements and in the indentures governing the 2028 Convertible Notes and 2030 Convertible Notes. The repurchase program may be limited, suspended or discontinued at any time without prior notice. Repurchases of our common stock pursuant to our share repurchase program could affect our stock price and increase its volatility. Additionally, our share repurchase program could diminish our cash reserves, which may impact our ability to finance future growth and to pursue possible future strategic opportunities and acquisitions. Although our share repurchase program is intended to enhance long-term stockholder value, there is no assurance that it will do so.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedRisk Factors
If a conversion request occurs, we have the intent and ability to refinance the amounts that may become due with respect to the 2028 Convertible Notes using available borrowing capacity under the Revolving Credit Facility. As such, the obligations associated with the 2028 Convertible Notes were classified as a long-term liability on the Consolidated Balance Sheets as of December 31, 2024. As of December 31, 2024, the borrowing capacity under our Revolving Credit Facility was $668.7 million, which exceeded the $500.0 million outstanding principal amount of the 2028 Convertible Notes. Even if holders of the 2028 Convertible Notes do not elect to convert their notes, or if our available borrowing capacity under our Revolving Credit Facility were to fall below the outstanding principal amount of the 2028 Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2028 Convertible Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedRisk Factors
Our business is also subject to potential increased costs and expenses and others other risks resulting from existing and potential future U.S. and foreign legislation, regulations regulations, trade agreements, tariffs, trade wars, import restrictions, boycotts, embargoes, government investigations, trade policies and trade agreements compliance matters relating to the products we manufacture outside of the U.S and import into the U.S. and other materials we import, import for the production of products, including the tariffs on steel and copper that the U.S. has imposed, the imposed and other tariffs that the new current U.S. presidential administration has imposed or threatened to impose, particularly relating to imports into the U.S. from Canada, Mexico (where we currently manufacture a significant portion of our products) and China, Ireland, and other quotas, duties, tariffs or taxes or restrictions on imports, all or any of which could adversely affect our operations, increase the costs of products that we manufacture outside the U.S. or adversely impact our profits or margins. China.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
If an event (including any weather weather, natural disaster or natural disaster-related event adverse climate change-related events, war or terrorism, civil unrest, disruption in utilities and other services affecting our facilities or a resurgence future pandemic, epidemic, outbreak of the COVID-19 pandemic a contagious disease or other similar pandemic event) public health crisis) occurred that resulted in material damage, loss or incapacitation of one or more of these manufacturing facilities or if we lacked sufficient labor to fully operate any of our facilities, we may not be able to transfer the manufacture of the relevant products to another facility or location in a cost-effective or timely manner, if at all. all, which could materially and adversely affect our business.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
In either case, and in other cases, our obligations under the 2028 Convertible Notes and Notes, the 2030 Convertible Notes, the indenture governing the 2028 Convertible Notes could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that holders of our common stock may view as favorable.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Additionally, new products and technologies that we develop may not be rapidly accepted because of industry-specific factors, including the need for regulatory clearance, entrenched patterns of clinical practice and practice, uncertainty over third-party reimbursement, reimbursement and our competitors developing products that provide better features, clinical outcomes or economic value than those that we currently offer or subsequently develop, and we may not be able to recover all or a meaningful part of our investment in the new products and technologies.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The holders of our 2028 Convertible Notes have had the ability to, and may in the future continue to have the ability to, convert their notes at their option prior to the scheduled maturities and the holders of our 2030 Convertible Notes may in the future have the ability to convert their notes at their option prior to the scheduled maturities.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Our failure to comply with applicable government regulations could also result in cessation of portions or all of our operations, impositions of fines and restrictions on our ability to carry on or expand our operations. operations, seizures or recalls of our products or those of our customers, inability to sell our products and adverse publicity affecting both us and our customers.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Our 2028 In addition, our 2030 Convertible Notes have in the past been and currently are through March 31, 2025, and may in the future become, will become convertible at the option of their holders under certain circumstances.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Whether the 2028 Convertible Notes or the 2030 Convertible Notes will be convertible in any future period will depend on the satisfaction satisfaction, with respect to the 2028 Convertible Notes, of this condition or or, with respect to the 2030 Convertible Notes, another conversion condition at such time.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Certain provisions of the Inflation Reduction One Big Beautiful Bill Act passed in 2022, (OBBA), including a 15% corporate alternative minimum tax, Net CFC Tested Income (formerly GILTI), as well as the similar 15% global minimum tax under the Organization for Economic Co-operation and Development (“OECD”) Pillar Two Global Anti-Base Erosion Rules, may impact our income tax expense, profitability, and capital allocation decisions and may negatively impact our effective tax rate.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The option counterparties for the capped call transactions for the 2028 Convertible Notes and the 2030 Convertible Notes are financial institutions, and we will be subject to the risk that any or all of them might default under the with respect to any such capped call transactions.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Due to the complex nature of our business, and due to policies we have in place allowing certain of our employees to work from home from time to time, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Our The price of our common stock may fluctuate significantly for numerous reasons, including the fluctuation of our operating results results, which have fluctuated in the past and are likely to continue to fluctuate from quarter to quarter, making forecasting future performance difficult and resulting in volatility in our common stock price.
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
We depend heavily on a limited number of customers, and if we lose any of them or they significantly reduce their business with us, we would lose a substantial portion of our revenues.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
In 2026, we expect sales growth to be impacted by lower sales related to three new products due to lower than anticipated market adoption. We believe the magnitude of these changes on multiple products at the same time is highly unusual.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On March 18, 2025, we issued $1.0 billion in aggregate principal amount of 1.875% Convertible Senior Notes due in 2030 (the “2030 Convertible Notes”). The total net proceeds from the issuance of the 2030 Convertible Notes, after deducting initial purchasers' discounts and commissions and debt issuance costs, were $976.1 million. We used $71.0 million of the net proceeds from the offering to fund the cost of entering into capped call transactions relating to the 2030 Convertible Notes.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
We used a portion of the remaining net proceeds from the issuance of the 2030 Convertible Notes to exchange $383.7 million in aggregate principal amount of our outstanding 2.125% Convertible Senior Notes due in 2028 (the “2028 Convertible Notes” and together with the “2030 Convertible Notes” the “Convertible Notes”) for an aggregate cash exchange consideration of $384.4 million in cash and 1,553,806 shares of common stock (the “Note Exchange Transactions”). The Note Exchange Transactions were considered an induced conversion and, as a result, we recorded $46.7 million during 2025 in induced conversion expense within Other loss, net in the Consolidated Statements of Operations. Contemporaneously with the Note Exchange Transactions, we terminated a portion of the capped call transactions related to the 2028 Convertible Notes and received 436,963 shares of common stock. We allotted the remainder of the net proceeds to pay the down our revolving credit facility and five-year “term A” loan.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On December 4, 2025, we acquired certain assets of Biocoat. Prior to the acquisition, Biocoat was a privately-held manufacturer specializing in high value surface coating technology platforms, including UV and thermal cure hydrophilic coatings.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On February 28, 2025, we acquired substantially all of the assets and assumed certain liabilities of VSi . Prior to the acquisition, VSi was a privately-held full-service provider of parylene coating solutions, primarily focused on complex medical device applications.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The following table presents selected financial information derived from our Consolidated Financial Statements, contained in Item 8, “Financial Statements and Supplementary Data,” of this report, for the periods presented (dollars in thousands, except per share amounts):Change 2025 vs. 2024 2025 2024 $ % Cardio & Vascular $ 1,107,084 $ 949,576 $ 157,508 16.6% Cardiac Rhythm Management & Neuromodulation 668,803 660,610 8,193 1.2% Other Markets 77,750 106,410 (28,660) (26.9)% Total sales 1,853,637 1,716,596 137,041 8.0% Cost of sales 1,353,251 1,257,582 95,669 7.6% Gross profit 500,386 459,014 41,372 9.0% Gross profit as a % of sales 27.0 % 26.7 % Operating expenses: Selling, general and administrative 211,748 185,202 26,546 14.3% SG&A as a % of sales 11.4 % 10.8 % Research, development and engineering 49,499 53,425 (3,926) (7.3)% RD&E as a % of sales 2.7 % 3.1 % Restructuring and other charges 17,875 12,149 5,726 47.1% Total operating expenses 279,122 250,776 28,346 11.3% Operating income 221,264 208,238 13,026 6.3% Operating expense as a % of sales 15.1 % 14.6 % Operating income as a % of sales (“Operating margin”) 11.9 % 12.1 % Interest expense 43,206 56,374 (13,168) (23.4)% (Gain) loss on equity investments, net (550) 780 (1,330) NM Other loss, net 53,212 3,521 49,691 NM Income from continuing operations before income taxes 125,396 147,563 (22,167) (15.0)% Provision for income taxes 22,566 26,510 (3,944) (14.9)% Effective tax rate 18.0 % 18.0 % Income from continuing operations $ 102,830 $ 121,053 $ (18,223) (15.1)% Income from continuing operations as a % of sales 5.5 % 7.1 % Diluted earnings per share from continuing operations $ 2.89 $ 3.40 $ (0.51) (15.0)%
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The following discussion is a comparison between results for the years ended December 31, 2025 and 2024. For a discussion of our results of operations for the year ended December 31, 2024 compared to the year ended December 31, 2023, please refer to Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 20, 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales for 2025 increased $8.2 million, or 1%, in comparison to 2024, with Cardiac Rhythm Management and Neuromodulation growing at market, offset by the planned decline of an early spinal cord simulation neuromodulation finished implantable pulse generator (non-emerging) customer, announced in 2020. Foreign currency exchange rate fluctuations did not have a material impact on CRM&N sales for 2025 in comparison to 2024.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
(a)Compensation and benefits increased primarily due to annual merit increases, acquisitions, leadership transition costs, and enterprise resource planning (“ERP”) implementation costs. Leadership transition costs primarily include incremental costs associated with executive leadership transitions. ERP implementation costs relate to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The provision for income taxes was $22.6 million and $26.5 million for the years ended December 31, 2025 and 2024, respectively. The decrease in the tax provision was primarily due to lower net income before taxes, a recognized increase in the impact of deductible stock based compensation, net of limitations, an increase in R&D tax credits and tax benefits associated with realized foreign tax credits, the year over year change in unrecognized tax benefits, and the impact of earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, partially offset by the impact of the net nondeductible induced conversion expenditures incurred as a result of the induced conversion from the exchange of the 2028 Convertible Notes and an increase in global minimum tax (Pillar 2).
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Cash and cash equivalents at December 31, 2025 decreased by $29.4 million from December 31, 2024. Cash generated by operating activities of $196.1 million was primarily offset by purchases of property, plant and equipment of $91.0 million, $50.0 million of repurchases of common stock, and tax withholding payments related to net share settlements of restricted stock unit awards of $16.9 million. The payment of the cash portion of the purchase price for each of the 2025 acquisitions totaling $178.9 million was fully funded by borrowings on our Revolving Credit Facility. Net proceeds of $976.1 million from the issuance of our 2030 Convertible Notes were utilized to purchase capped call options relating to the 2030 Convertible Notes, exchange of a portion of our 2028 Convertible Notes, and pay down our Revolving Credit Facility and TLA Facility. Net of the above noted acquisition and debt-related activity, we paid a net principal amount of $68.0 million on our Senior Secured Credit Facility in 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedMD&A
On October 1, 2023, we acquired substantially all of the assets and assumed certain liabilities of InNeuroCo, a recognized leader in neurovascular catheter innovation with strong development and manufacturing capabilities. InNeuroCo’s expertise and highly differentiated neurovascular catheter innovation complements our existing capabilities and market focus. Consistent with our strategy, the addition of InNeuroCo further increased our ability to provide enhanced solutions to our customers in the neurovascular catheter space.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
On April 6, 2022, we acquired Aran, a recognized leader in proprietary medical textiles, high precision biomaterial coverings and coatings as well as advanced metal and polymer braiding, Aran delivers development and manufacturing solutions for implantable medical devices. The acquisition of Aran further increased our ability to offer complete solutions for complex delivery and therapeutic devices in high growth cardiovascular markets such as structural heart, neurovascular, peripheral vascular, and endovascular as well as general surgery.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
During 2022, we announced plans to exit our portable medical market (the “Portable Medical Exit”) to enhance profitability and reallocate manufacturing capacity to support growth. Since that time, we have been working closely with impacted customers to support the transition of these products to other suppliers. Due to quality and regulatory requirements, we expected it would take three to four years to complete this transition. We currently expect Portable Medical sales to begin to wind down with the final sales and market exit occurring in 2025. Portable Medical sales are included in our Other Markets product line sales.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
As a result of the Electrochem divestiture, the results of operations of the Electrochem business have been classified as discontinued operations for all periods presented. Intersegment sales to Electrochem that were previously eliminated in consolidation have been treated as third-party sales and are included in sales from continuing operations as we will continue to supply the Electrochem business with certain specified products following its divestiture. Prior period amounts have been reclassified to conform to the continuing operations reporting presentation.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
During the fourth quarter of 2024, we began referring to our “Advanced Surgical, Orthopedics & Portable Medical” product line as the “Other Markets” product line, to better capture the evolving nature of our products and ongoing strategic focus. The name change has no impact on financial information previously reported.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales for 2024 increased $47.7 million, or 8%, in comparison to 2023. CRM&N sales for 2024 were driven by double-digit neuromodulation growth from emerging customers with premarket approval products and normalized low single-digit cardiac rhythm management growth.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
(e)The increase in bank fees and charges was driven by increased fees related to our factoring and supplier financing arrangements, primarily due to higher volume under both arrangements during 2024 compared to 2023.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
2024 2023 Change Restructuring charges(a) 4,013 5,874 (1,861) Acquisition and integration costs(b) 8,941 3,444 5,497 Other general expenses(c) (805) 2,110 (2,915) Total restructuring and other charges $ 12,149 $ 11,428 $ 721
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (income) loss, net for 2024 and 2023 were net losses of $3.2 million and $1.0 million, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedMD&A
The increase Operating Activities - During 2025, we generated cash from operations of $25.0 $196.1 million, compared to $205.2 million was the result of in 2024, as a $27.3 $56.7 million increase in net income adjusted for non-cash items such as depreciation and amortization, partially amortization was offset by a $2.3 $65.8 million decrease in cash flow provided by changes in operating assets and liabilities.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
In addition, Amount for 2024 includes loss recoveries of $1.2 million recorded during the 2023 amount includes $2.0 million second quarter of property loss and related expenses resulting from 2024 relating to property damage which occurred in the fourth quarter of 2023 at one of our manufacturing facilities.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Our future results of operations and liquidity could be materially adversely affected by uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, elevated changes in interest rates, disruptions in the commodities’ markets or in supply chain as a result of the conflict between Russia and wars in Ukraine and conflicts in the Middle East, including Israel and Iran, the tensions in Asia relating to China and Taiwan, and the introduction of or changes in tariffs or trade barriers.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Investing Activities – The $32.0 $75.3 million increase in net cash used in investing activities was primarily attributable to an increase in net cash paid for acquisitions, acquisitions and a decrease of cash received from the 2024 sale of Electrochem, partially offset by decreased purchases of property, plant and equipment and net cash proceeds from the sale of Electrochem. equipment.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
However, a significant increase in the discount rate, decrease in the terminal growth rate, increase in tax rates, decrease in the royalty rate or substantial reductions in our end-markets and volume assumptions, or increases in our cost assumptions could have a negative impact on the estimated fair values of either value of our tradenames reporting unit and require us to recognize impairments of these indefinite-lived intangible assets an impairment loss in a future period.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Subsequent to the end of the 2024, on On January 7, 2025, we acquired substantially all of the assets and assumed certain liabilities of certain subsidiaries of Katahdin Industries, Inc., including its main operating subsidiary, Precision Coating LLC (collectively “Precision”). Precision.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Other (income) loss, net primarily includes gains/losses reflects certain items not directly related to our core operations, including foreign currency gains and losses from the impact of exchange rates on transactions denominated in foreign currencies. currencies and other non-core items.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
(b)Amount Amount for 2024 primarily includes acquisition expenses of $5.5 million, primarily related to the Pulse and Precision Coating (completed in January 2025) acquisitions, and $3.4 million of integration expenses of $3.4 million, primarily related to the InNeuroCo and Pulse acquisitions. expenses.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
For the Greatbatch Medical tradename, the The excess of the estimated fair value over carrying value (expressed as a percentage of carrying value) was significantly in excess of its carrying value of $20 million by approximately 354% as of December 31, 2024. 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Other Markets sales for 2024 were flat 2025 decreased $28.7 million, or 27%, in comparison to 2023, as 2024, driven by the decline in Portable Medical from the multi-year exit announced in 2022 was offset by the Pulse acquisition. 2022.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Investing activities for 2024 included 2025 include net cash paid of $178.9 million for the Precision, VSi and Biocoat acquisitions, compared to net cash paid of $138.5 million during 2024 for the Pulse acquisition.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Electrochem, (“Electrochem”), which focused on nonmedical applications for the energy, military and environmental sectors, represented substantially all of the assets and operations in our previously reported Non-Medical reporting segment. sectors.
Read it in 10-K Feb 23, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ITGR/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.